- Third asset to advance into clinical trials, validating broad potential of Launch-iT platform
- All subjects treated with first dose of AVX70371 Launch-iT, as part of multiple dosing schedule
- Potential first-in-class treatment that could form part of functional cure for over 250 million patients suffering from chronic hepatitis B virus (HBV) infection
Leuven, Belgium, June 5, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the start of clinical development with AVX70371 for chronic hepatitis B virus (HBV) infection.
The phase I RUBY study (NCT06989788) will evaluate the safety, tolerability and immunogenicity of repeated injections of AVX70371 in 16 healthy adult volunteers at the…